secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097555
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results
--------------------------------------------------------------------------------

- Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
- Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).
- FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.
- Cash $514.4M provides runway into 2028.
- Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/0001193125-26-097555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer